Literature DB >> 29610751

Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?

Michel Farnier1.   

Abstract

Entities:  

Year:  2018        PMID： 29610751      PMCID： PMC5879519          DOI： 10.21037/atm.2018.01.02

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; Philip Barter; Rafael Carmena; Prakash Deedwania; Jean-Charles Fruchart; Steven Haffner; Judith Hsia; Andrei Breazna; John LaRosa; Scott Grundy; David Waters
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

2.  Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Authors:  B Cariou; L A Leiter; D Müller-Wieland; G Bigot; H M Colhoun; S Del Prato; R R Henry; F J Tinahones; A Letierce; L Aurand; J Maroni; K K Ray; M Bujas-Bobanovic
Journal:  Diabetes Metab       Date:  2017-03-24       Impact factor: 6.041

Review 3.  2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors:  Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2016-04-01       Impact factor: 24.094

4.  Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Authors:  Naveed Sattar; David Preiss; Jennifer G Robinson; C Stephen Djedjos; Mary Elliott; Ransi Somaratne; Scott M Wasserman; Frederick J Raal
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-08       Impact factor: 32.069

Review 5.  Lipid control in patients with diabetes mellitus.

Authors:  D John Betteridge
Journal:  Nat Rev Cardiol       Date:  2011-03-15       Impact factor: 32.419

6.  Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Authors:  Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

7.  Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.

Authors:  Michel Farnier; Daniel Gaudet; Velichka Valcheva; Pascal Minini; Kathryn Miller; Bertrand Cariou
Journal:  Int J Cardiol       Date:  2016-08-18       Impact factor: 4.164

8.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.

Authors:  Robert A Scott; Nicholas J Wareham; Luca A Lotta; Stephen J Sharp; Stephen Burgess; John R B Perry; Isobel D Stewart; Sara M Willems; Jian'an Luan; Eva Ardanaz; Larraitz Arriola; Beverley Balkau; Heiner Boeing; Panos Deloukas; Nita G Forouhi; Paul W Franks; Sara Grioni; Rudolf Kaaks; Timothy J Key; Carmen Navarro; Peter M Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; Jose-Ramón Quirós; Elio Riboli; Olov Rolandsson; Carlotta Sacerdote; Elena C Salamanca; Nadia Slimani; Annemieke Mw Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Mark I McCarthy; Inês Barroso; Stephen O'Rahilly; David B Savage; Naveed Sattar; Claudia Langenberg
Journal:  JAMA       Date:  2016-10-04       Impact factor: 56.272

9.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Authors:  Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245

10.  Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Authors:  Lawrence A Leiter; Bertrand Cariou; Dirk Müller-Wieland; Helen M Colhoun; Stefano Del Prato; Francisco J Tinahones; Kausik K Ray; Maja Bujas-Bobanovic; Catherine Domenger; Jonas Mandel; Rita Samuel; Robert R Henry
Journal:  Diabetes Obes Metab       Date:  2017-10-10       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.